The listing below shows our latest News Items and is updated regularly. If you wish to post a news item please select the 'Post News' button on the right. The displayed news feed starts on 1st August 2016. Older items can be found here.
We are pleased to present below all posts archived in 'June, 2017'. If you still can't find what you are looking for, try using the search box.
USA Pharma (EUSA), a specialty pharmaceutical company with a focus on oncology and oncology supportive care, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of FOTIVDA® (tivozanib) for the management of adult patients with advanced renal cell carcinoma (RCC).
Read the rest of entry »
Upon implementation of the new reimbursement codes, which is expected in the next 21 days, the French Ministry of Health and Social Affairs will provide reimbursement
Summit presents data from phase 1 clinical programme of Ezutromid at the European Paediactric Neurology Society Congress.
Philadelphia, USA – June 22, 2017. Serialization – Best Practices for Global Commercial Supply in an Evolving Market is the theme of the next free, specialist webinar from leading pharmaceutical outsourcing provider PCI Pharma Services (Thursday, June 29, 10-11am EDT / 3-4pm GMT).
AMSBIO has introduced a range of purified cancer exosome samples to help researchers study the role of exosomes in cancer development and metastasis.
Oxford, UK - PsiOxus Therapeutics, Ltd. (PsiOxus), the cancer therapeutics company, today announced expansion of operations into a 21,000 sq ft state-of-the-art facility on the Abingdon Science Park in Oxfordshire, UK. Additionally, PsiOxus announced the opening of a new US facility in Plymouth Meeting near Philadelphia, Pennsylvania. This dual expansion will allow PsiOxus to accelerate the research and development of novel immune-oncology products in both the UK and the US.
Local HealthScience communications consultancy recognized in Top 1000 Companies to Inspire Britain report
Oxford University are seeking financial support for the first UK BIOMOD team. In addition to the support they have received from the university, they are seeking industry sponsorship.
Oxford, UK, 7th June, 2017: Isansys Lifecare, the leader in new generation wireless patient monitoring systems, today announces the establishment of Isansys Lifecare Europe GmbH.
Located in the Brandenburg-Berlin Cluster - Europe's largest and most diversified source of new technology and a hotspot for life sciences - the new company is now fully operational and is offering Isansys’ real-time and predictive patient data solutions to the German-speaking healthcare markets now preparing for digital reform.
The aim of the facility is to help reshape the future of healthcare across Europe for patients and healthcare professionals.
(Oxford, UK and Conshohocken, US, 5 June 2017) Immunocore Limited, the world’s leading TCR company developing biological drugs to treat cancer, infectious diseases and autoimmune diseases today announces compelling single agent clinical data from the intra-patient dose escalation Phase I clinical trial of its lead programme, IMCgp100, which was presented in a poster session at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago on June 3 2017.
OBN aims to provide sector NEWS that is relevant to our Membership. We filter information from a variety of sources, publish items ourselves and will publish items of News from our Members. Press releases about OBN can be found here.
Future Blends are looking for an OBN member company who could help them strip solvent from one of their process streams. Initially looking at a 1 tonne scale. If you can help, or know of someone who might be able to then please contact Shane O’Leary at Future Blends. email@example.com.
This is an impromptu noticeboard to let people know about events, other things that are happening, perhaps lab equipment for sale etc. Just drop an email to us, firstname.lastname@example.org, and we will post.